{"name": "bluebird bio",
 "permalink": "genetix-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/genetix-pharmaceuticals",
 "homepage_url": "http://www.bluebirdbio.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "bluebirdbio",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 1992,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@bluebirdbio.com",
 "phone_number": "(617) 491 5601",
 "description": "",
 "created_at": "Sat Mar 13 02:38:16 UTC 2010",
 "updated_at": "Tue Apr 30 11:51:47 UTC 2013",
 "overview": "\u003Cp\u003EGenetix Pharmaceuticals Renamed bluebird bio\u003C/p\u003E\n\n\u003Cp\u003EGenetix is a specializes in gene therapy, looking to develop breakthrough treatments for severe genetic disorders. The company\u00e2\u20ac\u2122s platform treats the cause of genetic diseases by placing a healthy gene into the patient\u0026#8217;s extracted bone marrow stem cells, and transplanting these corrected stem cells back into the patient. Genetix\u0026#8217;s lead clinical product is Lenti-D for Adrenoleukodystrophy (ALD), also known as Lorenzo\u0026#8217;s Oil disease, which is now in clinical development.  The results of the ongoing ALD trial, based upon work conducted by the French National Institute of Health and Medical Research (INSERM), were named to Science Magazine\u0026#8217;s \u0026#8220;Scientific Breakthroughs of 2009.\u0026#8221; Genetix has in-licensed the technology from INSERM, and plans to initiate pivotal studies in both the U.S. and Europe. In addition to ALD, Genetix is conducting Phase I/II trials with its LentiGlobin\u00e2\u201e\u00a2 product in Thalassemia, one of the most prevalent human genetic disorders. To date, all patients receiving the full therapy with both products have been cured and are healthy.  The company\u00e2\u20ac\u2122s proprietary stem cell processing, GMP manufacturing and gene therapy vector technologies are also applicable to treating other genetic diseases.  \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       45],
      "assets/images/resized/0008/0169/80169v2-max-150x150.png"],
     [[226,
       69],
      "assets/images/resized/0008/0169/80169v2-max-250x250.png"],
     [[226,
       69],
      "assets/images/resized/0008/0169/80169v2-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Nick",
      "last_name": "Leschly",
      "permalink": "nick-leschly",
      "image": null}},
   {"is_past": false,
    "title": "Board of Directors",
    "person":
     {"first_name": "John",
      "last_name": "Maraganore",
      "permalink": "john-maraganore-2",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$134M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.fiercebiotech.com/story/genetix-raises-35m-advance-gene-therapies/2010-03-11?utm_medium=rss\u0026utm_source=rss",
    "source_description": "Genetix raises $35M to advance gene therapies",
    "raised_amount": 35000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 3,
    "funded_day": 12,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Third Rock Ventures",
         "permalink": "third-rock-ventures-2",
         "image":
          {"available_sizes":
            [[[150,
               78],
              "assets/images/resized/0005/0700/50700v1-max-150x150.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-250x250.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Genzyme Ventures",
         "permalink": "genzyme-ventures",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0002/8655/28655v1-max-150x150.png"],
             [[155,
               52],
              "assets/images/resized/0002/8655/28655v1-max-250x250.png"],
             [[155,
               52],
              "assets/images/resized/0002/8655/28655v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "TVM Capital",
         "permalink": "tvm-capital",
         "image":
          {"available_sizes":
            [[[150,
               35],
              "assets/images/resized/0003/0797/30797v1-max-150x150.png"],
             [[221,
               53],
              "assets/images/resized/0003/0797/30797v1-max-250x250.png"],
             [[221,
               53],
              "assets/images/resized/0003/0797/30797v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Forbion Capital Partners",
         "permalink": "forbion-capital-partners",
         "image":
          {"available_sizes":
            [[[150,
               60],
              "assets/images/resized/0010/0907/100907v1-max-150x150.png"],
             [[200,
               80],
              "assets/images/resized/0010/0907/100907v1-max-250x250.png"],
             [[200,
               80],
              "assets/images/resized/0010/0907/100907v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Easton Capital",
         "permalink": "easton-capital",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0001/6203/16203v3-max-150x150.jpg"],
             [[208,
               72],
              "assets/images/resized/0001/6203/16203v3-max-250x250.jpg"],
             [[208,
               72],
              "assets/images/resized/0001/6203/16203v3-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://www.live-pr.com/en/bluebird-bio-secures-additional-r1048856638.htm",
    "source_description": "bluebird bio Secures Additional $30 Million in Financing; ARCH Venture Partners Joins Investor Team ",
    "raised_amount": 30000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 4,
    "funded_day": 20,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "ARCH Venture Partners",
         "permalink": "arch-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               31],
              "assets/images/resized/0003/6165/36165v2-max-150x150.png"],
             [[250,
               51],
              "assets/images/resized/0003/6165/36165v2-max-250x250.png"],
             [[300,
               62],
              "assets/images/resized/0003/6165/36165v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Third Rock Ventures",
         "permalink": "third-rock-ventures-2",
         "image":
          {"available_sizes":
            [[[150,
               78],
              "assets/images/resized/0005/0700/50700v1-max-150x150.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-250x250.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "TVM Capital",
         "permalink": "tvm-capital",
         "image":
          {"available_sizes":
            [[[150,
               35],
              "assets/images/resized/0003/0797/30797v1-max-150x150.png"],
             [[221,
               53],
              "assets/images/resized/0003/0797/30797v1-max-250x250.png"],
             [[221,
               53],
              "assets/images/resized/0003/0797/30797v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Forbion Capital Partners",
         "permalink": "forbion-capital-partners",
         "image":
          {"available_sizes":
            [[[150,
               60],
              "assets/images/resized/0010/0907/100907v1-max-150x150.png"],
             [[200,
               80],
              "assets/images/resized/0010/0907/100907v1-max-250x250.png"],
             [[200,
               80],
              "assets/images/resized/0010/0907/100907v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Easton Capital",
         "permalink": "easton-capital",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0001/6203/16203v3-max-150x150.jpg"],
             [[208,
               72],
              "assets/images/resized/0001/6203/16203v3-max-250x250.jpg"],
             [[208,
               72],
              "assets/images/resized/0001/6203/16203v3-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "d",
    "source_url": "http://in.finance.yahoo.com/news/bluebird-bio-secures-60-million-103000423.html",
    "source_description": "bluebird bio Secures $60 Million in Oversubscribed Financing",
    "raised_amount": 60000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 7,
    "funded_day": 25,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Deerfield Partners",
         "permalink": "deerfield-partners",
         "image":
          {"available_sizes":
            [[[150,
               36],
              "assets/images/resized/0027/2381/272381v1-max-150x150.png"],
             [[250,
               61],
              "assets/images/resized/0027/2381/272381v1-max-250x250.png"],
             [[268,
               66],
              "assets/images/resized/0027/2381/272381v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "RA Capital Management",
         "permalink": "ra-capital-management",
         "image":
          {"available_sizes":
            [[[150,
               37],
              "assets/images/resized/0008/4805/84805v2-max-150x150.png"],
             [[230,
               58],
              "assets/images/resized/0008/4805/84805v2-max-250x250.png"],
             [[230,
               58],
              "assets/images/resized/0008/4805/84805v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "ARCH Venture Partners",
         "permalink": "arch-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               31],
              "assets/images/resized/0003/6165/36165v2-max-150x150.png"],
             [[250,
               51],
              "assets/images/resized/0003/6165/36165v2-max-250x250.png"],
             [[300,
               62],
              "assets/images/resized/0003/6165/36165v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Third Rock Ventures",
         "permalink": "third-rock-ventures-2",
         "image":
          {"available_sizes":
            [[[150,
               78],
              "assets/images/resized/0005/0700/50700v1-max-150x150.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-250x250.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "TVM Capital",
         "permalink": "tvm-capital",
         "image":
          {"available_sizes":
            [[[150,
               35],
              "assets/images/resized/0003/0797/30797v1-max-150x150.png"],
             [[221,
               53],
              "assets/images/resized/0003/0797/30797v1-max-250x250.png"],
             [[221,
               53],
              "assets/images/resized/0003/0797/30797v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Forbion Capital Partners",
         "permalink": "forbion-capital-partners",
         "image":
          {"available_sizes":
            [[[150,
               60],
              "assets/images/resized/0010/0907/100907v1-max-150x150.png"],
             [[200,
               80],
              "assets/images/resized/0010/0907/100907v1-max-250x250.png"],
             [[200,
               80],
              "assets/images/resized/0010/0907/100907v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Ramius Advisors",
         "permalink": "ramius-advisors",
         "image":
          {"available_sizes":
            [[[150,
               56],
              "assets/images/resized/0010/3115/103115v1-max-150x150.png"],
             [[165,
               62],
              "assets/images/resized/0010/3115/103115v1-max-250x250.png"],
             [[165,
               62],
              "assets/images/resized/0010/3115/103115v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://in.finance.yahoo.com/news/bluebird-bio-awarded-9-3-110000301.html",
    "source_description": "bluebird bio Awarded $9.3 Million From the California Institute for Regenerative Medicine to Further Gene Therapy Clinical Development",
    "raised_amount": 9300000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 10,
    "funded_day": 27,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "California Institute for Regenerative Medicine",
         "permalink": "california-institute-for-regenerative-medicine",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0004/8573/48573v1-max-150x150.jpg"],
             [[250,
               83],
              "assets/images/resized/0004/8573/48573v1-max-250x250.jpg"],
             [[399,
               134],
              "assets/images/resized/0004/8573/48573v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "840 Memorial Drive",
    "address2": "",
    "zip_code": "02139",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer",
    "stoned_year": 2010,
    "stoned_month": 9,
    "stoned_day": 9,
    "source_url": "http://www.tmcnet.com/usubmit/2010/09/09/4999602.htm",
    "source_text": "",
    "source_description": "Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "bluebird bio",
      "permalink": "genetix-pharmaceuticals"}},
   {"description": "collaborating with French firm G\u00c3\u00a9n\u00c3\u00a9thon in finding manufacturing solutions for gene therapy products and lentiviral vectors",
    "stoned_year": 2010,
    "stoned_month": 12,
    "stoned_day": 14,
    "source_url": "http://www.masshightech.com/stories/2010/12/13/daily27-Bluebird-bio-French-firm-team-in-gene-therapy-manufacturing.html",
    "source_text": null,
    "source_description": "Bluebird bio, French firm team in gene therapy manufacturing",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "bluebird bio",
      "permalink": "genetix-pharmaceuticals"}},
   {"description": "Bluebird bio forms potential $4.2M deal with French Muscular Dystrophy Association",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 16,
    "source_url": "http://www.masshightech.com/stories/2011/03/14/daily37-Bluebird-bio-forms-potential-42M-deal-with-French-Muscular-Dystrophy-Association.html",
    "source_text": "",
    "source_description": "Bluebird bio forms potential $4.2M deal with French Muscular Dystrophy Association",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "bluebird bio",
      "permalink": "genetix-pharmaceuticals"}},
   {"description": "appointed its first scientific advisory board (SAB) members today",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 21,
    "source_url": "http://www.masshightech.com/stories/2011/03/21/daily12-Bluebird-bio-names-first-SAB-members-expanding-clinical-trials.html",
    "source_text": null,
    "source_description": "Bluebird bio names first SAB members, expanding clinical trials",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "bluebird bio",
      "permalink": "genetix-pharmaceuticals"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        103],
       "assets/images/resized/0008/0168/80168v1-max-150x150.jpg"],
      [[250,
        173],
       "assets/images/resized/0008/0168/80168v1-max-250x250.jpg"],
      [[450,
        311],
       "assets/images/resized/0008/0168/80168v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}